Targeting a key metabolic regulator in acute myeloid leukemia
Official title: Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia
Funded at Versiti Wisconsin, INC. · NIH-11010051 · Data updated 2026-11-12
This study is looking at how a protein called SIRT5 helps blood cancer cells survive, with the hope of finding new ways to treat acute myeloid leukemia (AML) and improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $352,688 |
| NIH project number | 3R01CA254354-06S1 |
| Project ID | NIH-11010051 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who may not have responded well to existing therapies.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research investigates the role of SIRT5, a metabolic regulator, in acute myeloid leukemia (AML), a type of blood cancer with low survival rates. The study aims to identify new therapeutic targets by examining how AML cells depend on SIRT5 for survival, particularly in the protective environment of the bone marrow. By using advanced techniques like shRNA screening, researchers will test primary AML cells to understand their vulnerabilities and how they adapt to current treatments. The goal is to develop more effective therapies that can overcome resistance mechanisms in AML.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve survival rates for patients with acute myeloid leukemia.
How similar studies have gone: Other research has shown promise in targeting metabolic regulators in cancer, suggesting that this approach could be effective, although the specific targeting of SIRT5 in AML is relatively novel.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Deininger, Michael W. — Versiti Wisconsin, INC.
- Study coordinator: Deininger, Michael W.
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.